1,000,000 Shares in PepGen, Inc. $PEPG Bought by Kalehua Capital Management LLC

Kalehua Capital Management LLC purchased a new position in PepGen, Inc. (NASDAQ:PEPG) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 1,000,000 shares of the company’s stock, valued at approximately $1,770,000. PepGen accounts for approximately 1.3% of Kalehua Capital Management LLC’s investment portfolio, making the stock its 19th biggest position.

Other institutional investors have also recently made changes to their positions in the company. Burkehill Global Management LP bought a new position in shares of PepGen during the 3rd quarter worth about $46,000. China Universal Asset Management Co. Ltd. raised its stake in PepGen by 94.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,202 shares of the company’s stock worth $73,000 after buying an additional 5,453 shares during the period. Jefferies Financial Group Inc. acquired a new position in PepGen during the 4th quarter worth approximately $89,000. Militia Capital Partners LP acquired a new position in PepGen during the 3rd quarter worth approximately $72,000. Finally, Trexquant Investment LP bought a new position in PepGen in the fourth quarter worth approximately $158,000. Institutional investors and hedge funds own 58.01% of the company’s stock.

PepGen Stock Performance

Shares of NASDAQ:PEPG opened at $1.93 on Monday. The stock has a market cap of $133.50 million, a PE ratio of -1.10 and a beta of 1.88. The stock’s fifty day simple moving average is $1.76 and its two-hundred day simple moving average is $3.39. PepGen, Inc. has a 1-year low of $1.01 and a 1-year high of $7.80.

PepGen (NASDAQ:PEPG) last posted its earnings results on Tuesday, May 12th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.05. On average, sell-side analysts forecast that PepGen, Inc. will post -1.2 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. Craig Hallum began coverage on PepGen in a report on Tuesday, June 16th. They set a “buy” rating and a $11.00 price objective for the company. Wedbush cut their target price on PepGen from $5.00 to $4.00 and set an “outperform” rating on the stock in a report on Wednesday, May 13th. HC Wainwright restated a “buy” rating on shares of PepGen in a research note on Thursday, May 21st. Wall Street Zen upgraded shares of PepGen from a “sell” rating to a “hold” rating in a report on Sunday, June 7th. Finally, Weiss Ratings downgraded shares of PepGen from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 2nd. Six investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $11.50.

PepGen Company Profile

PepGen, Inc (NASDAQ: PEPG) is a clinical-stage biotechnology company headquartered in San Diego, California. The company is developing precision gene editing therapies to address rare genetic diseases by combining advanced prime editing modalities with proprietary delivery technologies. PepGen’s platform is designed to achieve targeted and durable correction of disease-causing mutations in vivo, with the goal of providing long-lasting therapeutic benefit after a single administration.

The company’s lead development programs include PPG-001 for mucopolysaccharidosis type II (Hunter syndrome) and PPG-002 for mucopolysaccharidosis type I (Hurler syndrome).